Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Heart

• Publication date

  2007-12-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/hrt.2007.122325PMID 18070940
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial.

  2008cited by this paper
• Low rate of sex-specific result reporting in cardiovascular trials.

  2007cited by this paper
• Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials

  2007cited by this paper
• AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute.

  2006influential reference
• AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.

  2006cited by this paper
• Perspectives on dyslipidemia and coronary heart disease in women.

  2005cited by this paper
• Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

  2005influential reference
• Opportunity for Intervention to Achieve American Heart Association Guidelines for Optimal Lipid Levels in High-Risk Women in a Managed Care Setting

  2005cited by this paper
• High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

  2005cited by this paper
• Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/Ameri

  2005cited by this paper
• Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology

  2004cited by this paper
• Drug treatment of hyperlipidemia in women.

  2004cited by this paper
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

  2004influential reference
• Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?

  2004cited by this paper
• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

  2004cited by this paper
• Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.

  2003cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

  2002cited by this paper
• Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease.

  2001cited by this paper
• The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

  2000cited by this paper
• Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project

  2000cited by this paper
• The effect of hormone replacement therapy on metabolism of lipoprotein remnants in postmenopausal women.

  2000cited by this paper
• Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.

  1999cited by this paper
• The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk.

  1999cited by this paper
• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

  1999cited by this paper
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

  1998cited by this paper
• Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.

  1998cited by this paper
• Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

  1997cited by this paper
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• National Cholesterol Education Program, second report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults.

  1995cited by this paper
• National Cholesterol Education Program, second report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults.

  1995cited by this paper

• HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.

  2023cites this paper
• LDL-cholesterol target levels achievement in high-risk patients: An (un)expected gender bias.

  2023cites this paper
• Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women

  2021cites this paper
• Challenges in Optimizing Lipid Management in Women

  2021cites this paper
• Inferior control of low-density lipoprotein cholesterol in women is the primary sex difference in modifiable cardiovascular risk: A large-scale, cross-sectional study in primary care.

  2021cites this paper
• Individual trends in LDL-C control in patients with previous myocardial infarction

  2020cites this paper
• The risk of cancer in statin users : a clinical and genetic approach

  2019cites this paper
• Challenges in Cardiovascular Risk Prediction and Stratification in Women

  2019cites this paper
• Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?

  2018cites this paper
• Tailoring cardiovascular risk assessment and prevention for women: One size does not fit all

  2017cites this paper
• Pharmacological interventions for heart failure in people with chronic kidney disease.

  2016cites this paper
• Comparison of Adherence to Guideline-Based Cholesterol Treatment Goals in Men Versus Women.

  2016cites this paper
• Do We Need a Different Approach to Assess Cardiovascular Risk in Women

  2016cites this paper
• Drivers of the Sex Disparity in Statin Therapy in Patients with Coronary Artery Disease: A Cohort Study

  2016cites this paper
• 9. Statins in the treatment and prevention of cardiovascular diseases

  2016cites this paper
• Serial Optical Coherence Tomography and Intravascular Ultrasound Analysis of Gender Difference in Changes of Plaque Phenotype in Response to Lipid-Lowering Therapy.

  2016cites this paper
• Gender Disparities in Lipid-Lowering Therapy in Cardiovascular Disease: Insights from a Managed Care Population

  2016cites this paper
• NATIONAL EVIDENCE-BASED GUIDELINE ON SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES Blood pressure lowering , lipid modification and anti-thrombotic therapy

  2015cites this paper
• National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.

  2015cites this paper
• Primary and Secondary Prevention of Ischemic Heart Disease in Women

  2015cites this paper
• Considering gender in prescribing statins: what do physicians need to know?

  2015cites this paper
• HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

  2014cites this paper
• Classification of Cardiovascular Disease Risk and Cardiovascular Disease Prevention in Women

  2014cites this paper
• Gender differences in achieving optimal lipid goals in patients with coronary artery disease.

  2014cites this paper
• Reducing Residual Risk in Secondary Prevention of CVD

  2012cites this paper
• Drugs for Cardiovascular Disease Prevention in Women

  2012cites this paper
• Lipid lowering efficacy of atorvastatin.

  2012cites this paper
• Meta-analysis of statin effects in women versus men.

  2012cites this paper
• Reducing residual risk in secondary prevention of cardiovascular disease.

  2012cites this paper
• Benefit of Intensive Statin Therapy in Women: Results From PROVE IT-TIMI 22

  2011cites this paper
• Prevention of Ischemic Heart Disease in Women

  2011cites this paper
• Tratamiento de la dislipemia en grupos especiales: ancianos y embarazadas

  2011cites this paper
• Menopause, estrogen, statins, and the immune system.

  2011cites this paper
• Does Pay for Performance Improve Cardiovascular Care in a “Real-World” Setting?

  2011cites this paper
• Gender differences in the treatment of ischemic heart disease.

  2011cites this paper
• Gender Differences in Coronary Risk Factors and Risk Interventions

  2011cites this paper
• Modulating mesenchymal stromal cell function with cholesterol synthesis inhibitors.

  2011cites this paper
• Kadinlarda klinik çalişmalarin değerlendirilmesi Evaluation of clinical trials

  2010cites this paper
• Dyslipidémies et risque cardiovasculaire : données des études de prévention cardiovasculaire

  2010cites this paper
• Statin therapy in women: concerns and caution.

  2010cites this paper
• Strategie differenziate nelle popolazioni target: le donne

  2010cites this paper
• Rosuvastatin and vitamin D: might there be hypovitaminosis D on JUPITER?

  2010cites this paper
• [Evaluation of clinical trials].

  2010cites this paper
• Letter to the Editor

  2009cites this paper
• Review of the treatment of acute coronary syndrome in elderly patients

  2009cites this paper
• The TNT study, women and cancer.

  2009cites this paper
• Prevention of atrial fibrillation: another good reason to recommend statins to women?

  2009cites this paper
• Highly Sensitive C-Reactive Protein, Body Mass Index, and Serum Lipids in HIV-Infected Persons Receiving Antiretroviral Therapy: A Longitudinal Study

  2009cites this paper
• The role of statins for the primary and secondary prevention of coronary heart disease in women.

  2009cites this paper
• HEMORRHAGIC STROKE IN THE STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS STUDY

  2009cites this paper
• Embolic complication of Tako-Tsubo cardiomyopathy.

  2009cites this paper
• HEMORRHAGIC STROKE IN THE STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS STUDY

  2009cites this paper
• Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors.

  2009cites this paper
• Primary prevention of cardiovascular disease with statins: cautionary notes.

  2009cites this paper
• Clinical insights from the Treating to New Targets trial.

  2009cites this paper
• Response to ‘Thyrotoxicosis during sunitinib treatment for renal cell carcinoma’ by Grossmann et al.

  2009cites this paper
• Letter to the Editor

  2009cites this paper
• Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy

  2009cites this paper
• Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study

  2008cites this paper
• Drugs for cardiovascular disease prevention in women: implications of the AHA Guidelines--2007 Update.

  2008cites this paper
• Statins and cancer risk: decrease or increase?

  2008cites this paper
• AJM onlineLetterThe Reply

  2008cites this paper
• Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?

  2008cites this paper
• Cardiovascular disease prevention tailored for women

  2008cites this paper
• Embolic complication of Tako-Tsubo cardiomyopathy

  year unknowncites this paper